Phase 1 First-in-Human Dose Escalation and Dose Expansion Study of KLS-1 (64Zinc Aspartate) in Patients With Cancer and Neurodegenerative Diseases.

Document Type

Article

Publication Date

10-1-2022

Publication Title

Cureus

Keywords

california; pni; santa monica

Abstract

Background KLS-1 is zinc (Zn) aspartate enriched with isotope 64Zn to 99.2% mass fraction of total zinc. KLS-1 is intended as a novel therapeutic approach for patients with a variety of diseases including but not limited to different forms of cancer and neurodegenerative diseases. The purpose of this first-in-human study was to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics (PK) in patients with medical disorders. Methods The study was designed as consisting of two consecutive parts: the dose escalation part and the dose expansion part. Adult patients with refractory glioblastoma, primary progressive aphasia/dementia, amyotrophic lateral sclerosis, Parkinson's disease (PD), and type 1 diabetes were included. KLS-1 formulated as a 10 mL water solution containing 26.42 mg/mL of 64zinc aspartate (that is equivalent to 5.184 mg/mL of 64Zn) was administered twice weekly in two-week cycles via two-hour intravenous (IV) infusion at various dose levels during the dose escalation part and twice weekly during five subsequent weeks in the dose expansion part. The study was conducted at Pan American Cancer Treatment Center (Tijuana, Mexico) in 2020 and had a duration of 10 months. Results A total of eight patients (all white/Caucasian) were enrolled in both parts of the study. A total of four patients who participated in the dose escalation part were dosed twice weekly at 1, 2, and 4 mg/kg in two-week cycles for each dose level with the dose increased to the next higher level in the subsequent cycle. Dose-limiting toxicities (DLTs) were defined at dose level 4 mg/kg due to treatment-emergent reversible adverse events that required medications for symptomatic relief. The most common drug-related toxicities that occurred in two or more patients (≥25%) were weakness (five patients), fatigue (four patients), dizziness (three patients), nausea (two patients), poor sleep (two patients), and abdominal discomfort (two patients). In the dose expansion part, a dose of 2 mg/kg administered twice weekly was investigated for five continuous weeks in four patients and was established as recommended phase 1b/2 dose. Systemic exposure to KLS-1 (area under the curve (AUC) and maximum serum concentration (Cmax)) increased from 1 to 4 mg/kg and showed a linear relationship. Conclusions Multiple doses of KLS-1 ranging from 1 to 2 mg/kg administered twice a week via intravenous infusion for up to five continuous weeks were safe and well tolerated in patients with different types of therapeutic conditions including but not limited to a few forms of cancer and Parkinson's disease, and the evaluated pharmacokinetic parameters exhibited favorable profile.

Keywords: 64zinc aspartate; amyotrophic lateral sclerosis; glioblastoma; light isotopes; neuro-oncology; neurology and neuro-oncology; oncology clinical trials; supportive oncology; zinc; zinc aspartate.

Conflict of interest statement

4600/60114 16/236,343 10857180 Pharmaceutical Composition for Improving Health, Cure Abnormalities and Degenerative Disease, Achieve Anti-aging Effect of Therapy and Therapeutic Effect on Mammals and Method Thereof 4600/60113 16/210,790 Antibacterial Composition and Its Use in Treating Bacterial Infections 4600/60108 15/613,109 10226484 Antibacterial Composition and Its Use in Treating Bacterial Infections 4600-60101 15/486,026 10183041 Antibacterial Composition and Its Use in Treating Bacterial Infections 4600-009PCTUS 16/972,169 Allowed Compound, Agent and Composition for the Suppression of Cancer Growth 4600-011PCT PCT/US19/55770 Method of Treating Parkinson’s and Other Neurodegenerative Diseases 4600-006US 14/833,114 9861659 Pharmaceutical Composition for Improving Health, Cure Abnormalities and Degenerative Disease, Achieve Anti-aging Effect of Therapy and Therapeutic Effect on Mammals and Method Thereof 4600-014USCON 17/113,904 Pharmaceutical Composition for Improving Health, Cure Abnormalities and Degenerative Disease, Achieve Anti-aging Effect of Therapy and Therapeutic Effect on Mammals and Method Thereof 4600-016PCT PCT/US19/67743 Composition and Method for the Prevention and Treatment of Obesity 4600-016US 16/722,167 10799530 Composition and Method for the Prevention and Treatment of Obesity 4600-016USCON 17/064,443 Composition and Method for the Prevention and Treatment of Obesity 4600-017PCT PCT/US19/62803 Method of Preventing the Development of Melanoma 4600-017US 16/692,584 Method of Preventing the Development of Melanoma 4600-018PCT PCT/US19/67746 Composition and Method for the Prevention and Treatment of Type 2 Diabetes 4600-018US 16/722,225 Allowed 10/28/2021 Composition and Method for the Prevention and Treatment of Type 2 Diabetes 4600-019PCT PCT/US19/67754 Method of Treating Nonalcoholic Steatohepatitis 4600-019US 16/722,249 Method of Treating Nonalcoholic Steatohepatitis 4600-020PCT PCT/US19/67766 Composition and Method for the Treatment of Type I Diabetes 4600-020US 16/722,295 10933091 Composition and Method for the Treatment of Type I Diabetes 4600-021P 63/009,714 Not yet Method of Preventing or Treating Viral Infections 4600-023PCT PCT/US21/24433 Foods to Promote Better Health and/or to Maintain Homeostasis and Method of Production Thereof 4600-023US 17/214,346 Foods to Promote Better Health and/or to Maintain Homeostasis and Method of Production Thereof 4600-024PCT PCT/US21/24440 Method of Treating Alzheimer’s Disease 4600-024US 17/214,377 Method of Treating Alzheimer’s Disease

Clinical Institute

Cancer

Clinical Institute

Neurosciences (Brain & Spine)

Department

Oncology

Department

Neurosciences

Link to Full Text

PSJH Full Text

Share

COinS